Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals
- PMID: 19926957
- PMCID: PMC3388940
- DOI: 10.1097/QAD.0b013e3283323941
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals
Abstract
Objective: To estimate whether HIV-infected pregnant women were at an increased risk of hepatotoxicity when taking nevirapine (NVP)-containing regimens compared with HIV-infected pregnant women taking antiretroviral therapy (ART) not containing NVP.
Methods: This analysis included HIV-infected pregnant women on ART from two multicenter, prospective cohorts: the Women and Infants Transmission Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials protocol P1025. Multivariate Cox proportional hazards regression models were used to investigate the association between NVP use and hepatotoxicity. NVP use was dichotomized as use or no use and further categorized according to ART exposure history. We investigated two outcomes: any liver enzyme elevation (LEE) (grade 1-4) and severe LEE (grade 3-4).
Results: A total of 1229 women with ART use during pregnancy were studied, 218 (17.7%) of whom received NVP. Among the women receiving NVP, 137 (62.8%) were NVP naive. Twenty-nine women (13.3%) who received NVP developed any LEE and one (0.5%) developed severe LEE. Of the 1011 women on non-NVP regimens, 145 (14.3%) developed any LEE and 14 (1.4%) developed severe LEE. There were no maternal deaths. In univariate models, LEE was not significantly associated with CD4 cell count above 250 cells/mul or NVP use. In adjusted multivariate models, no significant increased risk of LEE (any or severe) in women taking NVP was detected as compared to those taking other ART regardless of prior exposure history.
Conclusion: We did not observe an increased risk of hepatotoxicity among HIV-infected pregnant women on NVP versus other ART, including women who were ART naive.
Similar articles
-
Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.S Afr Med J. 2012 Oct 8;102(11 Pt 1):855-9. doi: 10.7196/samj.5700. S Afr Med J. 2012. PMID: 23116743 Review.
-
Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.J Int Assoc Physicians AIDS Care (Chic). 2012 Mar-Apr;11(2):142-9. doi: 10.1177/1545109711423445. Epub 2011 Oct 21. J Int Assoc Physicians AIDS Care (Chic). 2012. PMID: 22020069
-
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.PLoS One. 2010 Sep 7;5(9):e12617. doi: 10.1371/journal.pone.0012617. PLoS One. 2010. PMID: 20838641 Free PMC article.
-
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Cochrane Database Syst Rev. 2010. PMID: 20238370 Review.
-
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.AIDS. 2009 Nov 27;23(18):2425-30. doi: 10.1097/QAD.0b013e32832e34b1. AIDS. 2009. PMID: 19617813 Free PMC article.
Cited by
-
Liver injury associated with drug intake during pregnancy.World J Hepatol. 2021 Jul 27;13(7):747-762. doi: 10.4254/wjh.v13.i7.747. World J Hepatol. 2021. PMID: 34367496 Free PMC article. Review.
-
Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?J Int AIDS Soc. 2019 Sep;22(9):e25372. doi: 10.1002/jia2.25372. J Int AIDS Soc. 2019. PMID: 31529598 Free PMC article.
-
Safety of protease inhibitors in HIV-infected pregnant women.HIV AIDS (Auckl). 2013 Sep 27;5:253-62. doi: 10.2147/HIV.S33058. eCollection 2013. HIV AIDS (Auckl). 2013. PMID: 24101883 Free PMC article. Review.
-
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.J Int AIDS Soc. 2013 Sep 4;16(1):1-14. doi: 10.7448/IAS.16.1.18567. J Int AIDS Soc. 2013. PMID: 24008177 Free PMC article. Review.
-
Treating women with HIV: is it different than treating men?Curr HIV/AIDS Rep. 2012 Jun;9(2):171-8. doi: 10.1007/s11904-012-0116-x. Curr HIV/AIDS Rep. 2012. PMID: 22528764
References
-
- Bersoff-Matcha SJ, Miller WC, Aberg JA, van der Horst C, Hamrick HJ, Jr, Powderly WG, et al. Sex differences in nevirapine rash. Clin Infect Dis. 2001;32:124–9. - PubMed
-
- Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23–31. - PubMed
-
- Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive safety analysis of nevirapine in different populations of HIV-infected patients. J Acquir Immune Defic Syndr. 2003;34:S21–33. - PubMed
-
- Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825–829. - PubMed
-
- Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, et al. Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 RR000188/RR/NCRR NIH HHS/United States
- RR00645/RR/NCRR NIH HHS/United States
- U01 AI068632/AI/NIAID NIH HHS/United States
- U01 DA015054-12/DA/NIDA NIH HHS/United States
- N01-DK-8-0001/DK/NIDDK NIH HHS/United States
- M01 RR000188/RR/NCRR NIH HHS/United States
- U01 HD036117/HD/NICHD NIH HHS/United States
- U01 DA015054-09/DA/NIDA NIH HHS/United States
- HHSN267200800001C/HD/NICHD NIH HHS/United States
- U01 AI034841/AI/NIAID NIH HHS/United States
- U01AI068632/AI/NIAID NIH HHS/United States
- N01-HD-3-3365/HD/NICHD NIH HHS/United States
- U01 DA015054-11/DA/NIDA NIH HHS/United States
- U01 AI050274/AI/NIAID NIH HHS/United States
- U01 AI034858/AI/NIAID NIH HHS/United States
- U01 DA015054/DA/NIDA NIH HHS/United States
- M01 RR000645/RR/NCRR NIH HHS/United States
- U01 DA015054-10/DA/NIDA NIH HHS/United States
- N01AI85339/AI/NIAID NIH HHS/United States
- U01AI068616/AI/NIAID NIH HHS/United States
- HHSN267200800001G/DK/NIDDK NIH HHS/United States
- RR00188/RR/NCRR NIH HHS/United States
- U01 DA015054-13/DA/NIDA NIH HHS/United States
- U01 DA015053/DA/NIDA NIH HHS/United States
- U01 AI068616/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials